MRUS · Merus BV

-

Please sign in to comment on MRUS

1 Comment

Admin

4 years ago

Merus N.V is currently in a long term uptrend where the price is trading 3.3% above its 200 day moving average.

From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.1.

Merus N.V's total revenue rose by 20.0% to $9M since the same quarter in the previous year.

Its net income has dropped by 7.0% to $-28M since the same quarter in the previous year.

Finally, its free cash flow fell by 32.9% to $-25M since the same quarter in the previous year.

Based on the above factors, Merus N.V gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	NL0011606264
Sector	Healthcare
Industry	Biotechnology

Beta	1.03
Market Cap	3B
PE Ratio	None
Target Price	86.7857
Dividend Yield	None

ABOUT

Merus BV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS · Merus BV

-

Merus BV

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Merus BV using a moving average strategy